Antiobesity efficacy of GLP-1 receptor agonist liraglutide is associated with peripheral tissue-specific modulation of lipid metabolic regulators

BioFactors

Volumn 42, Issue 6, 2016, Pages 600-611

  Decara, Juan ^a,b   Arrabal, Sergio ^a,b   Beiroa, Daniel ^b,c   Rivera, Patricia ^a,b   Vargas, Antonio ^a,b   Serrano, Antonia ^a,b   Pavón, Francisco Javier ^a,b   Ballesteros, Joan ^d   Dieguez, Carlos ^b,c   Nogueiras, Rubén ^b,c   Rodríguez de Fonseca, Fernando ^a,b   Suárez, Juan ^a,b  

^a Institute of Biomedical Research in Malaga and BIONAND Nanomedicine Platform   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^d PROALT Parque Científico de Madrid PTM   (Spain)

Author keywords

adipose tissue; GLP 1; lipid metabolism; liver; obesity

Indexed keywords

CARNITINE PALMITOYLTRANSFERASE; CARNITINE PALMITOYLTRANSFERASE 1B; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; LIRAGLUTIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 1; UNCOUPLING PROTEIN 2; VERY LOW DENSITY LIPOPROTEIN; ANTIOBESITY AGENT; CYTOCHROME C OXIDASE; FATTY ACID; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; UCP1 PROTEIN, RAT; UCP2 PROTEIN, RAT;

ABDOMINAL WALL MUSCULATURE; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CALORIC INTAKE; CONTROLLED STUDY; DIET INDUCED OBESITY; DRUG EFFICACY; FAT CONTENT; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; LIPID HOMEOSTASIS; LIPID LIVER LEVEL; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPEATED DRUG DOSE; THERMOGENESIS; TRIACYLGLYCEROL BLOOD LEVEL; WHITE ADIPOSE TISSUE; AGONISTS; ANIMAL; ANTIBODY SPECIFICITY; DRUG EFFECTS; ENZYMOLOGY; LIVER; METABOLISM; OBESITY; PRECLINICAL STUDY; SPRAGUE DAWLEY RAT;

ANIMALS; ANTI-OBESITY AGENTS; DRUG EVALUATION, PRECLINICAL; ELECTRON TRANSPORT COMPLEX IV; ENERGY INTAKE; FATTY ACIDS; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; LIPID METABOLISM; LIRAGLUTIDE; LIVER; MALE; METABOLIC NETWORKS AND PATHWAYS; OBESITY; ORGAN SPECIFICITY; PPAR ALPHA; PPAR GAMMA; RATS, SPRAGUE-DAWLEY; THERMOGENESIS; UNCOUPLING PROTEIN 1; UNCOUPLING PROTEIN 2;

EID: 84971283657     PISSN: 09516433     EISSN: 18728081     Source Type: Journal    
DOI: 10.1002/biof.1295     Document Type: Article

References (48)

1. Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., et al. (2009) Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 374, 1606–1616.
2. Hare, K. J. and Knop, F. K. (2010) Incretin-based therapy and type 2 diabetes. Vitam. Horm., 84, 389–413.
3. Marre, M., Shaw, J., Brändle, M., Bebakar, W. M., Kamaruddin, N. A., et al. (2009) Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet. Med., 226, 268–278.
4. Mells, J. E. and Anania, F. A. (2013) The role of gastrointestinal hormones in hepatic lipid metabolism. Semin. Liver Dis., 33, 343–357.
5. Baggio, L. L. and Drucker, D. J. (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology, 132, 2131–2157.
6. Hayes, M. R., De Jonghe, B. C., and Kanoski, S. E. (2010) Role of the glucagon-like-peptide-1 receptor in the control of energy balance. Physiol. Behav., 100, 503–510.
7. Hayes, M. R., Kanoski, S. E., Alhadeff, A. L., and Grill, H. J. (2011) Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats. Obesity, 19, 1342–1349.
8. Holst, J. J. (2007) The physiology of glucagon-like peptide 1. Physiol. Rev., 87, 1409–1439.
9. Pyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., et al. (2014) GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology, 155, 1280–1290.
10. Vendrell, J., El Bekay, R., Peral, B., García-Fuentes, E., Megia, A., et al. (2011) Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance. Endocrinology, 152, 4072–4079.
11. Bradley, D. P., Kulstad, R., and Schoeller, D. A. (2010) Exenatide and weight loss. Nutrition, 26, 243–249.
12. Madsen, A. N., Hansen, G., Paulsen, S. J., Lykkegaard, K., Tang-Christensen, M., et al. (2010) Long-term characterization of the diet-induced obese and diet-resistant rat model: a polygenetic rat model mimicking the human obesity syndrome. J. Endocrinol., 206, 287–296.
13. Thum, T. and Anker, S. D. (2010) Liraglutide for weight loss in obese people. Lancet, 375, 551–552.
14. Beiroa, D., Imbernon, M., Gallego, R., Senra, A., Herranz, D., et al. (2014) GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK. Diabetes, 63, 3346–3358.
15. Lockie, S. H., Heppner, K. M., Chaudhary, N., Chabenne, J. R., Morgan, D. A., et al. (2012) Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signaling. Diabetes, 61, 2753–2762.
16. Nogueiras, R., Pérez-Tilve, D., Veyrat-Durebex, C., Morgan, D. A., Varela, L., et al. (2009) Direct control of peripheral lipid deposition by CNS GLP-1 receptor signaling is mediated by the sympathetic nervous system and blunted in diet-induced obesity. J. Neurosci., 29, 5916–5925.
17. López, M., Diéguez, C., and Nogueiras, R. (2015) Hypothalamic GLP-1: the control of BAT thermogenesis and browning of white fat. Adipocyte, 4, 141–145.
18. Jin, X., Xiang, Z., Chen, Y. P., Ma, K. F., Ye, Y. F., et al. (2013) Uncoupling protein and nonalcoholic fatty liver disease. Chin. Med. J., 126, 3151–3155.
19. Pheiffer, C., Jacobs, C., Patel, O., Ghoor, S., Muller, C., et al. (2016) Expression of UCP2 in Wistar rats varies according to age and the severity of obesity. J. Physiol. Biochem., 72, 25–32.
20. Sisley, S., Gutierrez-Aguilar, R., Scott, M., D'Alessio, D. A., Sandoval, D. A., et al. (2014) Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect. J. Clin. Invest., 124, 2456–2463.
21. Tudurí, E., Beiroa, D., Porteiro, B., López, M., Diéguez, C., et al. (2015) Acute but not chronic activation of brain glucagon-like peptide-1 receptors enhances glucose-stimulated insulin secretion in mice. Diabetes Obes. Metab., 17, 789–799.
22. Urbano, F., Filippello, A., Di Pino, A., Barbagallo, D., Di Mauro, S., et al. (2016) Altered expression of uncoupling protein 2 in glp-1-producing cells after chronic high glucose exposure: implications for the pathogenesis of diabetes mellitus. Am. J. Physiol. Cell. Physiol., 310, C558–67
23. Giralt, M. and Villarroya, F. (2016) Mitochondrial uncoupling and the regulation of glucose homeostasis. Curr. Diabetes Rev.
24. Gupta, N. A., Mells, J., Dunham, R. M., Grakoui, A., Handy, J., et al. (2010) Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology, 51, 1584–1592.
25. Panjwani, N., Mulvihill, E. E., Longuet, C., Yusta, B., Campbell, J. E., et al. (2013) GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice. Endocrinology, 154, 127–139.
26. Pedersen, J. and Holst, J. J. (2011) Glucagon like-peptide 1 receptor and the liver. Liver Int., 31, 1243–1245.
27. Mells, J. E., Fu, P. P., Sharma, S., Olson, D., Cheng, L., et al. (2012) Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet. Am. J. Physiol. Gastrointest. Liver Physiol., 302, G225–G235.
28. Sharma, S., Mells, J. E., Fu, P. P., Saxena, N. K., and Anania, F. A. (2011) GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy. PLoS One, 6, e25269.
29. Taher, J., Baker, C. L., Cuizon, C., Masoudpour, H., Zhang, R., et al. (2014) GLP-1 receptor agonism ameliorates hepatic VLDL overproduction and de novo lipogenesis in insulin resistance. Mol. Metab., 3, 823–833.
30. Parlevliet, E. T., Wang, Y., Geerling, J. J., Schröder-Van der Elst, J. P., Picha, K., et al. (2012) GLP-1 receptor activation inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high-fat-fed APOE*3-Leiden mice. PLoS One, 7, e49152.
31. Tanaka, K., Masaki, Y., Tanaka, M., Miyazaki, M., Enjoji, M., et al. (2014) Exenatide improves hepatic steatosis by enhancing lipid use in adipose tissue in nondiabetic rats. World J. Gastroenterol., 20, 2653–2663.
32. van Raalte, D. H., Li, M., Pritchard, P. H., and Wasan, K. M. (2004) Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future. Pharm. Res., 21, 1531–1538.
33. Crespillo, A., Alonso, M., Vida, M., Pavón, F. J., Serrano, A., et al. (2011) Reduction of body weight, liver steatosis and expression of stearoyl-CoA desaturase 1 by the isoflavone daidzein in diet-induced obesity. Br. J. Pharmacol., 164, 1899–1915.
34. Suárez, J., Rivera, P., Arrabal, S., Crespillo, A., Serrano, A., et al. (2014) Oleoylethanolamide enhances β-adrenergic-mediated thermogenesis and white-to-brown adipocyte phenotype in epididymal white adipose tissue in rat. Dis. Model Mech., 7, 129–141.
35. Mailloux, R. J. and Harper, M. E. (2011) Uncoupling proteins and the control of mitochondrial reactive oxygen species production. Free Radic. Biol. Med., 51, 1106–1115.
36. Poulsen, M. M., Larsen, J., Hamilton-Dutoit, S., Clasen, B. F., Jessen, N., et al. (2012) Resveratrol up-regulates hepatic uncoupling protein 2 and prevents development of nonalcoholic fatty liver disease in rats fed a high-fat diet. Nutr. Res., 32, 701–708.
37. Vida, M., Rivera, P., Gavito, A. L., Suárez, J., Pavón, F. J., et al. (2014) CB1 blockade potentiates down-regulation of lipogenic gene expression in perirenal adipose tissue in high carbohydrate diet-induced obesity. PLoS One, 9, e90016.
38. Baggio, L. L., Huang, Q., Brown, T. J., and Drucker, D. J. (2004) Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology, 127, 546–558.
39. Warnick, G. R., Knopp, R. H., Fitzpatrick, V., and Branson, L. (1990) Estimating low-density lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints. Clin. Chem., 36, 15–19.
40. Alonso, M., Serrano, A., Vida, M., Crespillo, A., Hernandez-Folgado, L., et al. (2012) Anti-obesity efficacy of LH-21, a cannabinoid CB(1) receptor antagonist with poor brain penetration, in diet-induced obese rats. Br. J. Pharmacol., 165, 2274–2291.
41. Sisley, S., Smith, K., Sandoval, D. A., and Seeley, R. J. (2014) Differences in acute anorectic effects of long-acting GLP-1 receptor agonists in rats. Peptides, 58, 1–6.
42. Minehira, K., Young, S. G., Villanueva, C. J., Yetukuri, L., Oresic, M., et al. (2008) Blocking VLDL secretion causes hepatic steatosis but does not affect peripheral lipid stores or insulin sensitivity in mice. J. Lipid Res., 49, 2038–2044.
43. Sozio, M. S., Liangpunsakul, S., and Crabb, D. (2010) The role of lipid metabolism in the pathogenesis of alcoholic and nonalcoholic hepatic steatosis. Semin. Liver Dis., 30, 378–390.
44. Hussain, M. M., Rava, P., Walsh, M., Rana, M., and Iqbal, J. (2012) Multiple functions of microsomal triglyceride transfer protein. Nutr. Metab. (Lond.), 9, 14.
45. Ding, X., Saxena, N. K., Lin, S., Gupta, N. A., and Anania, F. A. (2006) Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology, 43, 173–181.
46. Ben-Shlomo, S., Zvibel, I., Shnell, M., Shlomai, A., Chepurko, E., et al. (2011) Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. J. Hepatol., 54, 1214–1423.
47. Dehghan, A., van Hoek, M., Sijbrands, E. J., Hofman, A., and Witteman, J. C. (2008) High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care, 31, 361–362.
48. Johnson, R. J., Nakagawa, T., Sanchez-Lozada, L. G., Shafiu, M., Sundaram, S., et al. (2013) Sugar, uric acid, and the etiology of diabetes and obesity. Diabetes, 62, 3307–3315.